loading page

Olanzapine Substitution for Dexamethasone for Prevention of Chemotherapy Induced Nausea and Vomiting Prophylaxis in Children
  • +1
  • Catherine E. Pierson,
  • Kerri Row,
  • Anthony S. Zembillas,
  • Stefanie Thomas
Catherine E. Pierson
Cleveland Clinic

Corresponding Author:rennac@ccf.org

Author Profile
Kerri Row
Cleveland Clinic
Author Profile
Anthony S. Zembillas
Jazz Pharmaceuticals Inc
Author Profile
Stefanie Thomas
Cleveland Clinic
Author Profile

Abstract

This study compared the efficacy of three-drug antiemetic regimens (olanzapine, fosaprepitant, and 5-HT3 receptor antagonist versus dexamethasone, fosaprepitant, and 5-HT3 receptor antagonist) on chemotherapy-induced nausea and vomiting (CINV) in children. Complete response (CR) was defined as no emesis or use of rescue antiemetics. In the acute phase, 52% of patients in the olanzapine group achieved a CR compared to 63% in the dexamethasone group (p=0.354). In the delayed phase, CR was 80% versus 73% (p= 0.702), respectively. Olanzapine is an acceptable agent to use in place of dexamethasone when a patient is not a candidate for corticosteroid as CINV prophylaxis.